Development of Lipid-Engineered PSMA-Targeted Radioligands with Quinoline Scaffold
- 22 April 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 11132-11145
Abstract
Prostate-specific membrane antigen (PSMA) is highly overexpressed in prostate cancer, making it an effective diagnostic biomarker and therapeutic target for PCa. However, many PSMA-targeted small-molecule probes suffer from suboptimal tumor uptake and retention. In this study, a series of PSMA ligands were rationally designed and synthesized using classical lipidation and fatty acid modification strategies, and subsequently labeled with 68Ga/177Lu to address these limitations. Cellular studies and molecular docking simulations confirmed their PSMA specificity and protein-binding properties. In a PC-3 PIP xenograft mouse model, nine 68Ga-labeled PSMA-targeted radioligands were evaluated using PET imaging. Among them, [68Ga]Ga-PDA2-C6 and [68Ga]Ga-PDA1-1 demonstrated remarkable tumor accumulation and retention, with improved tumor-to-nontarget (T/NT) ratios. Biodistribution studies further revealed pronounced tumor retention of [177Lu]Lu-PDA2-C6 and [177Lu]Lu-PDA1-1. Overall, this proof-of-concept study validated that conjugating PSMA ligands with tailor-made lipid chain and fatty acids can markedly enhance tumor uptake and retention while maintaining a low level of kidney retention.Keywords
Funding Information
- Fujian Provincial Department of Science and Technology (2025Y0002)
- Fundamental Research Funds for the Central Universities (20720242010)
- National Natural Science Foundation of China (82372008)
- Xiamen University
- National High Level Hospital Clinical Research Funding (2025-PUMCH-D-003)
- Fujian Province
This publication has 40 references indexed in Scilit:
- Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic propertiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- The Lancet Commission on prostate cancer: planning for the surge in casesThe Lancet, 2024
- Prostate-Specific Membrane Antigen–Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic OutcomesEuropean Urology, 2023
- Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligandsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive TumorsBioconjugate Chemistry, 2018
- Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90Y-DOTA-EB-MCGBioconjugate Chemistry, 2018
- Semaglutide: First Global ApprovalDrugs, 2018
- Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapyProteomics – Clinical Applications, 2014
- A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urineThe Prostate, 2000